Silicon Leverage: Trump, TSMC, and the New Chip Power Play
Trump’s tariff remarks signal not just economic policy, but strategic leverage over TSMC.
BTC$60,654.00-0.59%
ETH$1,559.10-1.26%
USDT$0.9996-0.01%
USDC$0.9997+0.01%
XRP$1.09-1.35%
SOL$61.91-3.12%
TRX$0.3237+0.86%
FIGR_HELOC$1.03+0.46%
DOGE$0.0814-0.42%
HYPE$56.44-5.27%
USDS$0.9997-0.02%
LEO$9.44-1.44%
RAIN$0.0128-1.63%
XLM$0.2116+5.14%
CC$0.1627+9.72%
BTC$60,654.00-0.59%
ETH$1,559.10-1.26%
USDT$0.9996-0.01%
USDC$0.9997+0.01%
XRP$1.09-1.35%
SOL$61.91-3.12%
TRX$0.3237+0.86%
FIGR_HELOC$1.03+0.46%
DOGE$0.0814-0.42%
HYPE$56.44-5.27%
USDS$0.9997-0.02%
LEO$9.44-1.44%
RAIN$0.0128-1.63%
XLM$0.2116+5.14%
CC$0.1627+9.72%
Apple dodges Trump's 100% semiconductor tariffs through a strategic $100 billion U.S. manufacturing commitment.
Trump’s tariff remarks signal not just economic policy, but strategic leverage over TSMC.
Hinge Health stock surged over 12% in premarket trading after reporting Q2 2025 results that beat revenue expectations by $13.7 million.
SNAP and SMCI shares crashed in premarket trading following disappointing Q2 earnings results.
Palantir’s role in U.S. public-private governance has never been clearer, and PLTR stock is moving in lockstep.
Arteris stock surges in premarket trading after announcing a partnership with AMD.
Fortified by Toyota capital inflows, Joby Aviation is making all the right moves to launch a global air taxi service.
Steelcase stock soars 43% in premarket trading after HNI Corporation announces $2.2 billion acquisition deal at $18.30 per share.
So far, Apple’s AI strategy appears underfunded by contrast with the Big Tech cluster. Simultaneously, it is difficult to ignore AI’s underlying problems.
Coinbase beat Q2 earnings expectations by over 240% but saw shares fall 11% in premarket.
Amazon stock crashes 7.94% in premarket despite beating Q2 earnings expectations.
ARM Holdings shares crashed over 11% on Thursday after the chip designer provided weak Q2 earnings guidance and hinted at developing its own processors.
Ozempic-famed Novo Nordisk took over a $70 billion wipeout off its market value this week. Is this the beginning of a trend, or a great opportunity?